PharmaShots | Incisive News in 3 Shots

Subscribe Now

Advanced NSCLCs

Merck KGaA Reports EMA's Validation of MAA for Tepotinib to Treat Advanced NSCLC with METex14 Skipping Alterations

Merck KGaA Reports EMA's Validation of MAA for Tepotinib to Treat Advanced NSCLC with METex14 Skipping Alterations

November 27, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us